Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
The STEP program trials with semaglutide (a GLP-1-only agonist) and the SURMOUNT trials with tirzepatide (dual GIP/GLP-1 agonist) represent the strongest weight loss efficacy data in the history of pharmacotherapy for obesity
Updated November 14, 2024
But they just cant lose excess weight and keep it off
A comprehensive analysis published in PubMed Central compared metabolic and weight-loss outcomes across GLP-1based therapies
Retatrutide adds a third mechanism through glucagon receptor activation
US$ 21.67
US$ 24.25
US$ 23.41
US$ 28.56
US$ 25.08
